Substance Use Disorders During Pregnancy: Clinical Risks and Treatment

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Substance use disorders during pregnancy require coordinated addiction treatment, prenatal medicine, mental health care, and preparation for the postpartum period. Clinical decisions should identify the substance and pattern of use, distinguish a diagnosable disorder from exposure alone, address immediate threats such as overdose or medically dangerous withdrawal, and preserve treatments that protect the pregnant patient and developing fetus. For opioid use disorder, methadone and buprenorphine are recommended treatments; a sudden attempt to stop opioids can increase the risk of recurrence and medical complications. For alcohol, nicotine, cannabis, stimulants, and sedative-hypnotics, assessment and treatment differ substantially. The central clinical task is to protect two connected patients through sustained, individualized care rather than relying on a single screening result or an isolated detoxification episode. CDC, 2026: opioid treatment in pregnancy WHO: pregnancy substance-use guidelines

Pregnancy also changes the practical conditions under which a person seeks help. Nausea, pain, anxiety, previous trauma, transportation barriers, housing insecurity, fear of disclosure, and previous experiences with health services can influence access and continuity. These circumstances affect clinical engagement and the interpretation of observational research. An effective response begins with a respectful conversation, a careful diagnosis where indicated, and an explicit plan for treatment during pregnancy, birth, and the months after delivery. SAMHSA: clinical guidance for pregnant and parenting patients

What Is a Substance Use Disorder During Pregnancy?

A substance use disorder (SUD) is a clinically significant pattern of substance use involving impaired control, persistent use despite harm, craving or other substance-specific diagnostic features, and impairment or distress. Pregnancy does not create a separate diagnostic category for addiction. The same fundamental clinical criteria must be interpreted in the context of pregnancy, medical treatment, and expected physiological changes. A pregnant patient may use a substance without meeting criteria for a disorder, and a diagnosed disorder may remain active or enter remission while pregnancy-related care continues. The general distinctions between dependence, addiction, and misuse are developed in Substance Use Disorder vs Substance Misuse: Clinical and Everyday Terms.

Substance use describes exposure or consumption. Risky use describes a pattern associated with an increased probability of adverse effects. Substance misuse generally describes use outside medical directions or patterns judged harmful in a specified context; the term is used inconsistently and does not establish a diagnosis. A substance use disorder requires assessment of diagnostic criteria and clinical impact. The stakes of some exposures rise during pregnancy even when there is no addiction: alcohol exposure may affect fetal development, while prescribed opioids or sedatives may require careful management without any compulsive use. CDC: polysubstance use during pregnancy

Addiction, tolerance, physical dependence, and withdrawal

Addiction is a clinical and research concept emphasizing dysregulated motivation, impaired control, and continued use despite consequential harm. Tolerance describes diminished response or need for greater exposure to achieve a given pharmacological effect. Physical dependence is physiological adaptation that can produce withdrawal if a drug is reduced or stopped. Both tolerance and physical dependence may develop during medically appropriate treatment and are insufficient alone to establish an SUD. Withdrawal is a syndrome that follows reduction or cessation of a substance after adaptation; its severity and clinical implications differ dramatically across alcohol, benzodiazepines, opioids, nicotine, and cannabis.

This distinction has immediate consequences in prenatal practice. A person stabilized on prescribed methadone or buprenorphine may be physiologically dependent on medication while receiving evidence-based treatment for opioid use disorder. A person taking a benzodiazepine as prescribed may need supervised treatment changes because of physiological dependence even without meeting criteria for sedative use disorder. Conversely, someone may experience severe substance-related harm without a dramatic withdrawal syndrome. ACOG: opioid use and opioid use disorder in pregnancy ASAM: benzodiazepine tapering guideline

Pregnancy exposure is a separate clinical question

The diagnosis of a maternal disorder, the presence of a substance in a biological sample, and the estimation of fetal exposure answer different questions. A toxicology result may indicate recent exposure to a tested compound or metabolite, subject to detection windows and false results; it does not quantify impairment, establish a disorder, prove parenting incapacity, or identify the timing and magnitude of fetal effects. Exposure-related counseling therefore requires substance-specific evidence, patient history, and an assessment of alternatives, including the consequences of discontinuing prescribed care. USPSTF: unhealthy drug use screening

Why Pregnancy Requires an Integrated Clinical Approach

Maternal physiology changes throughout gestation, affecting blood volume, gastrointestinal absorption, renal clearance, protein binding, and metabolism of multiple drugs. Symptoms such as fatigue, nausea, insomnia, and changes in appetite may overlap with intoxication, withdrawal, medication effects, mood symptoms, or ordinary pregnancy experiences. A single symptom is therefore a poor substitute for longitudinal evaluation. Substance-specific treatment must be coordinated with obstetric assessment of blood pressure, fetal growth, gestational age, nutritional status, pregnancy complications, and prescribed medications. CDC: opioid use and pregnancy clinical guidance

Pregnancy can also be a period of sustained engagement with health care, offering opportunities to assess substance use repeatedly, establish collaborative goals, and treat concurrent depression, anxiety, trauma-related symptoms, or chronic pain. Where mental health conditions are present, they deserve their own clinical assessment. The broader scope of screening and treatment belongs to Perinatal Mental Health: Conditions, Symptoms, Screening, and Care, while this article addresses their consequences for addiction treatment and continuity.

A longitudinal rather than episodic model

Care is best organized across preconception, early pregnancy, later pregnancy, labor, neonatal observation, and the postpartum year. A patient may need different services at each transition: medication access and stabilization early in pregnancy, reassessment of pharmacokinetics and safety as gestation advances, coordinated pain treatment at delivery, neonatal monitoring after birth, and sustained addiction treatment once obstetric visits become less frequent. Planning these transitions reduces the risk of fragmented care. SAMHSA: postpartum OUD care transitions, 2026

Clinical Risks for the Pregnant Patient and Developing Fetus

Risk depends on the substance, dosage and frequency, route, pregnancy stage, co-occurring exposures, underlying disorders, and available care. In observational studies, substance use often co-occurs with tobacco exposure, variable prenatal care, mental health conditions, poverty, violence, infection risk, and medical comorbidity. Researchers must distinguish correlations in a complicated environment from a causal effect attributable to one substance. For that reason, findings about fetal growth, prematurity, neonatal adaptation, and long-term development require careful interpretation. CDC: polysubstance exposure and research limitations

For the pregnant patient, significant threats may include overdose, injury, cardiovascular complications, seizures or delirium during specific withdrawal syndromes, malnutrition, infectious complications related to injection, and recurrence of a psychiatric condition. Obstetric risks can include fetal growth restriction, preterm birth, placental problems, stillbirth, and complications associated with unstable health and exposure patterns. The magnitude and certainty of these risks vary by substance. Risk counseling should describe this heterogeneity and offer an actionable pathway to care. CDC: substance use during pregnancy

Placental exposure and developmental vulnerability

Many psychoactive substances or their metabolites cross the placenta and can affect fetal development or adaptation. Timing matters because organs, placental function, and neural circuits develop along changing trajectories. Chronic exposure and intermittent episodes of intoxication can have different biological implications. Maternal oxygenation, nutrition, stress physiology, and infection may also mediate outcomes. The clinical significance of these pathways cannot be inferred from the phrase prenatal exposure alone: measured outcomes depend on how exposure was defined and which confounders were addressed in the study. WHO: identification and management guidelines

Polysubstance exposure and drug interactions

Using multiple substances is common among people presenting for treatment. Opioids combined with alcohol, benzodiazepines, or other sedatives can intensify respiratory depression, while stimulant exposure may coexist with opioid contamination or use. Cannabis and tobacco are frequently reported together, complicating attribution of perinatal effects. Assessment should therefore examine all prescribed, nonprescribed, and recreational substances, including nicotine products, alcohol, supplements, and sedating medications. CDC: polysubstance use during pregnancy, 2026

Screening, Assessment, and Diagnosis

Universal, respectful conversations about alcohol, tobacco, cannabis, opioids, stimulants, sedatives, and nonmedical medication use should be part of routine prenatal care. Screening identifies people who may benefit from a fuller assessment; it is distinct from a diagnostic interview. The U.S. Preventive Services Task Force recommends questionnaire-based screening for unhealthy drug use in adults, including pregnant and postpartum adults, when effective diagnosis, treatment, or referral services are available. The recommendation specifically concerns asking questions rather than collecting biological specimens. USPSTF, 2020

A confidential, nonpunitive clinical conversation

A useful first assessment asks what substances have been used, whether use is current, how frequently and by what route, the timing of last exposure, any prescribed treatment, past withdrawal complications, previous treatment experience, and what the patient wishes to change. It also asks about overdose history, suicide risk, immediate safety, housing, partner violence, prenatal care, and available support. Clinicians should explain confidentiality and its legal limits before collecting sensitive information and should avoid promising protections that local law does not provide. ACOG's 2025 cannabis consensus recognizes that reporting practices, criminalization, and child welfare involvement can shape disclosure and may reproduce inequities. ACOG, 2025: cannabis clinical consensus

A positive screen may be followed by a structured substance-specific history, evaluation of diagnostic criteria, medication reconciliation, physical examination, and targeted tests when clinically indicated. Biological testing is sometimes appropriate for a defined medical question, but it requires informed attention to consent, detection limitations, confirmatory testing, and potential consequences. ACOG advises against using biological testing as universal cannabis screening. Patient-centered use of diagnostic tests can improve trust while preserving clinical safety. ACOG, 2025

Screening tools and their limitations

Validated questionnaires can structure inquiry, although accuracy differs by substance, setting, language, and population. Tools developed for general adult primary care should be interpreted cautiously if pregnancy-specific validation is limited. Screening for alcohol use and tobacco exposure also requires attention to risk at levels below a disorder threshold. When a screen suggests an SUD, clinicians assess impairment, loss of control, hazardous circumstances, withdrawal, and the broader course of use before diagnosing it. Screening does not replace comprehensive clinical judgment. USPSTF: evidence and recommendations

Differential diagnosis and comorbidities

Anxiety, depression, sleep disruption, hyperemesis, prescribed medication effects, acute infection, and obstetric emergencies can overlap with intoxication or withdrawal symptoms. A history of trauma can change how a patient experiences examinations and treatment. Clinicians should assess mental health symptoms independently, including thoughts of self-harm when indicated, and should investigate medical causes rather than attributing everything to substance use. Specific pathways for screening mental health conditions are described in Perinatal Mental Health Screening: When, How, and What Happens Next.

Opioid Use Disorder During Pregnancy

Opioid use disorder is a high-priority clinical condition because untreated disease can involve overdose, variable illicit drug exposure, infection, interrupted prenatal care, and repeated withdrawal. Current U.S. guidance recommends medication for opioid use disorder, generally methadone or buprenorphine, over withdrawal management alone during pregnancy. These medications reduce the destabilizing cycle of recurrent nonprescribed opioid use and support engagement with obstetric and addiction care. The broader diagnosis and long-term treatment principles belong to Opioid Use Disorder: Symptoms, Risks, and Treatment. CDC, 2026

Methadone and buprenorphine as established treatment

Methadone is a full opioid agonist delivered through regulated treatment systems, while buprenorphine is a partial agonist available in appropriate clinical settings. Both are recommended during pregnancy. Selection depends on treatment history, patient preference, prior stability, concurrent medication, availability, clinical complexity, and follow-up capacity. Some patients do best with methadone's structured delivery; others benefit from buprenorphine's formulation and care flexibility. A person already stable on effective treatment should have continuity discussed rather than being switched automatically because of pregnancy. ACOG, 2017 SAMHSA clinical guidance

A large U.S. Medicaid cohort comparing buprenorphine and methadone exposure found lower observed rates of neonatal withdrawal and several adverse birth outcomes among buprenorphine-exposed pregnancies, while measured serious maternal complications were similar. For example, neonatal abstinence syndrome was identified in approximately 52% of buprenorphine-exposed infants versus 69% of methadone-exposed infants near delivery. This study was observational, so residual differences between patients and care systems can influence estimates. It supports informed medication choice, not a requirement to change a stable patient's medication. Suarez et al., 2022

Pregnancy-related changes in distribution and metabolism can alter treatment needs, especially later in gestation. Clinicians monitor withdrawal symptoms, cravings, sedation, adherence, and concurrent use and adjust treatment based on clinical response. Medication should not be withheld because neonatal withdrawal might occur; treating maternal opioid use disorder is itself a major protective intervention. CDC: clinical guidance, 2025

Why withdrawal management alone is an inadequate treatment plan

A medically managed withdrawal episode may relieve immediate physiological dependence, but it does not by itself treat persistent craving, conditioned reinforcement, social triggers, or the long-term risk of recurrence. For pregnant patients with opioid use disorder, guidance favors ongoing medication treatment over taper-based withdrawal management because of the likelihood of recurrence and associated harms. Abrupt cessation of opioids can cause maternal withdrawal and fetal distress, among other risks. Decisions about any medication change require individualized medical supervision. CDC, 2026

Naltrexone and medication continuity

Naltrexone blocks opioid receptors and is an established medication for opioid use disorder outside pregnancy, but pregnancy-specific evidence is less extensive than for methadone or buprenorphine. For a person already stable on naltrexone when pregnancy is discovered, current guidance favors a collaborative risk-benefit discussion rather than an automatic change. Clinicians consider the risk of recurrence, the reasons for prior treatment choice, pregnancy circumstances, and the limits of fetal safety data. Initiation or transition between medications is a specialist decision. CDC, 2026

Naloxone, overdose, and immediate response

Suspected opioid overdose is an emergency. Inability to awaken a person, slow or absent breathing, blue or gray discoloration, and unresponsiveness require emergency medical services. Naloxone should be administered when opioid overdose is suspected and it is available, including during pregnancy; restoring ventilation and maternal oxygenation is urgent. Emergency personnel should assess airway and breathing, monitor recurrent toxicity, and evaluate the pregnancy. Overdose prevention education and access to naloxone belong in the care plan for patients at risk, including people prescribed opioid agonist therapy who might encounter contaminated drugs. CDC: opioid treatment and overdose prevention

The clinical profile and overdose dangers of synthetic opioids, including contamination of the unregulated supply, are examined in Fentanyl Exposure, Dependence, and Overdose: Clinical Risks. Discussion of fentanyl exposure in pregnancy should distinguish medically prescribed analgesia from illicit exposure and should not assume that all positive toxicology results imply an addiction diagnosis.

Alcohol Use Disorder, Alcohol Exposure, and Withdrawal

Alcohol can cause fetal harm without the pregnant patient meeting criteria for alcohol use disorder. There is no established safe amount or safe gestational time for alcohol exposure, and guidelines recommend avoiding alcohol during pregnancy. Fetal alcohol spectrum disorders encompass developmental and neurobehavioral consequences associated with prenatal exposure. At the same time, alcohol use disorder requires its own diagnosis and treatment planning, including assessment of consumption pattern, previous withdrawal, other medical conditions, and access to continued care. ACOG: FASD clinical questions Alcohol Use Disorder: Signs, Diagnosis, and Treatment

Alcohol withdrawal can be life-threatening

A physiologically dependent person who stops heavy alcohol use can develop severe withdrawal, including seizures and delirium. Pregnancy adds medical and fetal considerations to an already dangerous syndrome. Patients with a history of withdrawal seizures, delirium, sustained heavy use, significant medical illness, or signs of escalating withdrawal need urgent medical evaluation, and inpatient management may be appropriate. WHO describes supervised treatment for severe withdrawal in pregnancy and notes that medications used to prevent seizures or delirium require clinician oversight. No unsupervised taper or home detoxification schedule is appropriate for this article. WHO guidelines

Patients seeking alcohol cessation should receive compassionate and rapid access to prenatal and addiction care. After stabilization, counseling, relapse-prevention work, nutritional evaluation, and longitudinal treatment remain necessary. Medications commonly used for alcohol use disorder outside pregnancy have limited pregnancy-specific safety and effectiveness data, so the choice among medication, psychosocial intervention, and continued clinical monitoring is individualized. The separate withdrawal syndrome is discussed in Alcohol Withdrawal: Symptoms, Risks, and Medical Care.

Tobacco, Nicotine, and Vaping During Pregnancy

Smoking is associated with impaired fetal growth, preterm birth, and other adverse maternal and infant outcomes. Quitting at any time in pregnancy has potential benefit, with earlier cessation offering greater protection. Behavioral counseling has established efficacy for pregnant patients who smoke. The U.S. Preventive Services Task Force gives behavioral interventions a strong recommendation and finds the evidence insufficient to determine the overall balance of benefits and harms for smoking-cessation pharmacotherapy during pregnancy. USPSTF, 2021

A prenatal smoking-cessation plan can combine motivational work, structured counseling, practical trigger management, quitline support, and follow-up after birth. Nicotine replacement therapy may be considered through shared decision-making and close supervision when behavioral interventions alone are insufficient, after discussing continued smoking and the limitations of pregnancy safety data. Clinicians should distinguish tobacco combustion risks from nicotine exposure itself; neither vaping nor unregulated nicotine products can be assumed harmless in pregnancy. Detailed cessation techniques are addressed in How to Quit Smoking: Effective Medications and Behavioral Support. ACOG: tobacco and nicotine cessation during pregnancy

Cannabis Use and Cannabis Use Disorder During Pregnancy

Cannabis use during pregnancy has been associated in observational studies with adverse birth outcomes, including low birth weight and preterm birth, and there are concerns about later neurodevelopment. These studies face challenges from concurrent tobacco and alcohol use, exposure measurement, social confounding, and changing cannabis potency. Clinical counseling should communicate the potential risks and the uncertainty in causal effect estimates. Cannabis use may also be an attempt to manage nausea, pain, anxiety, or insomnia; care should address those symptoms with better-characterized options rather than assuming the substance has a verified prenatal therapeutic role. ACOG Clinical Consensus No. 10, 2025

The 2025 ACOG clinical consensus recommends universal interview-based screening, education about fetal and newborn risks, and support for cessation during pregnancy and lactation. It states there is no medical indication for cannabis use during these periods and advises against biological testing as a general screening method. The consensus also emphasizes the consequences of punitive responses to disclosure. Cannabis use disorder is diagnosed through a pattern of clinically meaningful impairment, not merely through a report of pregnancy exposure. Specific diagnostic and recovery concepts are examined in Cannabis Use Disorder: Symptoms, Diagnosis, and Recovery. ACOG, 2025

There is no established pharmacotherapy specifically approved to treat cannabis use disorder in pregnancy. Behavioral approaches, motivational interviewing, attention to environmental triggers, and treatment of co-occurring conditions form the practical basis of care. In patients with frequent use, abrupt discontinuation can produce irritability, anxiety, sleep difficulty, and appetite changes; these symptoms should be assessed without conflating them with obstetric emergencies. A focused scientific account appears in Cannabis Withdrawal: Symptoms, Duration, and Care.

Stimulant Use Disorders in Pregnancy

Stimulant use disorders involving methamphetamine or cocaine can present with cardiovascular symptoms, severe insomnia, agitation, malnutrition, and co-occurring psychiatric illness. Acute intoxication may include hypertension, chest pain, hyperthermia, arrhythmia, or psychosis, any of which can require emergency assessment. Pregnancy increases the need to evaluate maternal vital signs and fetal well-being. Clinicians should also ask about possible fentanyl contamination in the unregulated stimulant supply and offer overdose prevention where relevant. ASAM and AAAP stimulant use guideline

Contingency management has the strongest evidence among behavioral treatments for stimulant use disorder in general clinical populations. ASAM and AAAP recommend adapting treatment for pregnant patients, including parenting-focused and family-based supports, and considering incentives for prenatal attendance alongside substance-use treatment goals. Evidence for pregnancy-specific pharmacotherapy is substantially more limited, and medications used for other psychiatric indications are not automatically established treatments for stimulant addiction in pregnancy. ASAM and AAAP, 2024

Treatment should coordinate addiction counseling, nutrition, sleep management, prenatal follow-up, assessment of intimate partner violence and housing, and medical care for acute complications. Co-occurring hallucinations or delusions require careful differentiation among stimulant intoxication, stimulant-related psychosis, and an independent psychotic disorder. The independent diagnostic framework is developed in Substance-Induced Psychosis: Causes, Symptoms, and Treatment, while general stimulant treatment belongs to Stimulant Use Disorder: Methamphetamine, Cocaine, and Treatment.

Benzodiazepines, Sedative-Hypnotics, and Prescribed Medication

Patients may become physiologically dependent on benzodiazepines prescribed for anxiety, sleep, or seizure-related conditions. Dependence alone does not demonstrate benzodiazepine use disorder. Continued treatment may carry maternal and infant risks, while abrupt discontinuation can provoke severe withdrawal, seizures, or destabilization of the original condition. In pregnancy, medication changes require individualized assessment involving obstetric and relevant prescribing clinicians. The 2025 joint ASAM-led benzodiazepine tapering guideline provides pregnancy-specific considerations and emphasizes managing both the underlying clinical problem and withdrawal risk. ASAM: benzodiazepine tapering, 2025

Clinical decisions weigh the indication, current level of dependence, gestational timing, co-prescribed substances, and safer available treatments. Concomitant opioid and benzodiazepine exposure raises overdose risk through additive respiratory depression. A pregnancy diagnosis should trigger medication review rather than a blanket instruction to stop all psychotropic medicines. The existence of an evidence-based prescription is a distinct issue from use outside the prescription. CDC: opioid and polysubstance exposure

Treatment Principles Across Substance Classes

Treatment during pregnancy is effective when matched to the diagnosis and person's needs. The evidence base is substance-specific: methadone and buprenorphine have a central role in opioid use disorder; behavioral interventions have established value for tobacco cessation and many other disorders; contingency management is particularly supported in stimulant treatment; and medically supervised withdrawal is essential for some alcohol or sedative withdrawal states. One universal detoxification model cannot address these different clinical pathways. WHO pregnancy guidelines ASAM stimulant guideline

Integrated prenatal and addiction services

The strongest practical care design connects prenatal clinicians, addiction medicine, behavioral health, pharmacy, social work, neonatology, and pediatric follow-up. Integration can occur in a single clinic or through reliable referral pathways with shared goals and consent-based coordination. Patients benefit when appointment schedules, transportation, insurance or payment, medication access, and privacy are handled as core treatment concerns. A fragmented system can undermine an effective medication or counseling plan even when the clinical decision itself is correct. SAMHSA: perinatal OUD clinical guidance

A treatment plan should specify the disorder and current risk level, prenatal monitoring, substance-specific therapy, crisis arrangements, management of co-occurring conditions, and follow-up across the postpartum transition. Patient preferences and informed consent matter. Health systems should make treatment available before a crisis or a positive toxicology test, rather than requiring repeated proof of readiness. Reliable longitudinal contact is a therapeutic resource in itself.

Psychosocial treatments and evidence limits

Motivational interviewing can support collaborative discussion about ambivalence and practical behavior change. Cognitive behavioral approaches can identify cues, thoughts, emotional states, and routines that maintain use. Contingency management provides consistent reinforcement for defined treatment behaviors and has especially strong general-population evidence in stimulant use disorder. Peer support, parenting interventions, and family services can contribute to stability. The quality of pregnancy-specific evidence differs by treatment, population, and outcome; findings from nonpregnant adults require contextual application, not an assumption of identical effectiveness. ASAM and AAAP stimulant guideline

Medication and counseling are complementary for many patients, but the absence of immediate access to psychotherapy should not be used to withhold evidence-based medication for opioid use disorder. Equally, social support without clinical treatment is insufficient for a medically dangerous withdrawal syndrome. Matching interventions to risks and respecting continuity are central principles of safe care. CDC: treatment during pregnancy

Harm reduction as clinical prevention

Harm reduction measures can reduce injury and create opportunities for treatment. Depending on risk and local resources, they include naloxone access, overdose recognition, infectious-disease testing and treatment, sterile injection equipment through lawful services, vaccination, safer medication storage, and education about the danger of combining sedatives and opioids. Harm reduction should be presented as part of comprehensive maternal care rather than as an alternative that excludes treatment. The priorities are maintaining contact, preventing death and infection, and supporting the patient's goals. CDC: substance use during pregnancy

Trauma-informed care and social safety

Stigma can delay prenatal attendance and encourage nondisclosure, particularly where patients fear legal penalties or family separation. Trauma-informed care uses respectful language, explains procedures, seeks permission, maintains predictable contact, and offers choices when medically feasible. Clinicians can ask about partner coercion, exploitation, housing safety, financial barriers, and access to food without equating these conditions with personal failure. This matters clinically because external constraints influence both exposure and retention in treatment. ACOG, 2025: cannabis counseling and inequities

Recognizing Emergencies and Medically Dangerous Withdrawal

Pregnancy makes rapid triage essential when a person is unresponsive, breathing abnormally, severely confused, actively seizing, or experiencing severe chest pain, uncontrolled agitation, high fever, or severe withdrawal symptoms. Such presentations require emergency medical evaluation. Fetal monitoring and obstetric management are integrated with treatment of maternal oxygenation, circulation, glucose, temperature, and toxic exposure according to clinical circumstances. An emergency response should not be delayed while establishing whether diagnostic criteria for a chronic SUD are met. WHO pregnancy guidelines

Distinguishing intoxication, overdose, and withdrawal

Intoxication refers to acute physiological or behavioral effects after exposure. Overdose is an exposure producing potentially serious toxicity, which may include respiratory depression, seizures, arrhythmia, or altered consciousness depending on the substance. Withdrawal results from declining exposure after physiological adaptation; alcohol and benzodiazepine withdrawal may involve seizures or delirium, whereas opioid withdrawal is particularly destabilizing in pregnancy and demands expert assessment. Chronic substance use disorder is a longitudinal diagnosis that can coexist with any of these acute states. CDC: opioid use and pregnancy ASAM: benzodiazepine guideline

Labor, Delivery, and Pain Management

Birth planning should document current treatment, medication continuity, expected analgesia needs, neonatal monitoring, and communication among obstetric, anesthesiology, addiction, and pediatric teams. Patients taking methadone or buprenorphine typically continue treatment through labor and receive appropriate additional pain relief. Ongoing medication for opioid use disorder does not eliminate the need for labor analgesia, regional anesthesia, or individualized management of postoperative pain. Clinicians need to recognize interactions that may precipitate withdrawal in patients maintained on opioid agonists. ACOG, 2017: intrapartum recommendations

Labor care should remain respectful and clinically responsive, including for patients with past difficult experiences in hospital systems. A coordinated delivery plan can reduce missed doses, unexpected undertreatment of pain, and confusing messages about the newborn's care. Consent-based communication allows patients to understand which professionals will participate in decisions and why.

Neonatal Opioid Withdrawal and Other Newborn Concerns

Neonatal opioid withdrawal syndrome (NOWS) may occur when an infant exposed to opioids before birth experiences withdrawal after delivery. Symptoms can include irritability, abnormal sleep, feeding difficulty, tremors, and autonomic instability. The syndrome's probability and severity are influenced by multiple exposures and individual factors; it is not a direct measure of whether a pregnant patient received poor care. Importantly, anticipated neonatal withdrawal is not an indication to deny methadone or buprenorphine to a person with opioid use disorder. CDC: neonatal withdrawal overview

A randomized trial comparing methadone and buprenorphine in pregnancy found differences in neonatal treatment requirements, supporting the importance of neonatal outcomes in medication discussions. Later observational work also found lower rates of NOWS with buprenorphine than with methadone in its population, although the possibility of confounding remains. These results inform treatment selection; they do not outweigh the safety benefits of maintaining a medication that is already working for an individual. Jones et al., 2010 Suarez et al., 2022

Family-centered newborn observation

Newborn care may include observation, support for feeding and soothing, nonpharmacological care, and medication when clinically indicated. In a 26-hospital cluster-randomized trial, the Eat, Sleep, Console approach reduced time until medical readiness for discharge compared with usual care for eligible infants, without an increase in specified adverse safety outcomes through three months. As with any neonatal protocol, implementation depends on staffing, family support, infant eligibility, and local clinical standards. Young et al., 2023

Other newborn concerns are substance-specific. Alcohol exposure may be associated with fetal alcohol spectrum disorders; tobacco exposure is associated with growth and infant health risks; stimulant and sedative exposure may require individualized newborn evaluation. Predicting long-term development from one exposure label is scientifically inadequate, because outcomes are influenced by genetics, co-exposure, gestational age, caregiving environment, and subsequent medical and developmental support. CDC: polysubstance exposure

Breastfeeding and Substance Use Disorder Treatment

Breastfeeding recommendations require attention to the substance, current use, medication treatment, infant condition, and ongoing supports. Stable methadone or buprenorphine treatment is generally compatible with breastfeeding under established clinical guidance, and breastfeeding may support parent-infant bonding and some neonatal outcomes. Active nonprescribed sedative, opioid, or stimulant use changes the risk assessment substantially. Programs should establish consistent, nonstigmatizing protocols that consider toxicology data in context and enable individualized decisions. Academy of Breastfeeding Medicine Protocol No. 21, 2023

Cannabis deserves a particularly precise explanation. ACOG's 2025 consensus advises stopping cannabis use during lactation because of potential risks and limited long-term evidence, while stating that ongoing cannabis use alone is not an absolute contraindication to breastfeeding and should not automatically lead clinicians to discourage it. Lactation counseling must therefore discuss exposure reduction and infant health while considering the substantial benefits of breastfeeding and the patient's actual circumstances. ACOG: cannabis use during pregnancy and lactation, 2025

Breastfeeding planning should begin before delivery, coordinate with pediatric and addiction teams, and account for return to use, medication changes, and infant monitoring. Clinical circumstances can change quickly after birth. A supportive pathway for reassessment is preferable to an inflexible policy based on a single past exposure or diagnosis. Harris et al., 2023

The Postpartum Period: Continuity, Overdose Prevention, and Recovery

The months after delivery carry substantial clinical risk because sleep deprivation, changing routines, pain, depression or anxiety, reduced obstetric contact, insurance interruptions, and caregiving pressures may affect treatment engagement. People with opioid use disorder may face a heightened risk of overdose during the first postpartum year. Treatment plans should preserve medications, arrange follow-up before discharge, reassess overdose prevention resources, and make mental health care accessible. SAMHSA: Healthy Starts postpartum transitions, 2026

Medication continuation after delivery

Delivery alone is not a reason to stop methadone or buprenorphine. Ongoing treatment duration reflects clinical need and patient goals, and any later reduction should be carefully planned with specialists. Patients can benefit from consolidated appointments, telehealth where appropriate, reliable pharmacy arrangements, and warm handoffs from prenatal teams to continuing addiction and primary care. A lost appointment or an unexpected insurance change may carry clinical consequences, so discharge planning should make access concrete. CDC: OUD treatment before, during, and after pregnancy

Mood disorders, suicide risk, and family support

Depression, anxiety, trauma-related symptoms, and suicidality should be assessed on their own terms rather than presumed consequences of drug exposure. Postpartum depression and anxiety can coexist with substance use disorder and alter risk, treatment adherence, and infant care. Patients describing suicidal intent, severe confusion, inability to sleep with marked behavioral change, or psychotic symptoms require timely mental health evaluation; imminent danger requires emergency care. Clinical coverage of these distinct conditions appears in Postpartum Mental Health: Emotional Changes, Conditions, and Support and Substance Use Disorders and Suicide Risk: Evidence, Assessment, and Safety.

Family members can assist with transportation, medication access, childcare, recovery-support appointments, and emergency plans. Their role should be grounded in patient consent and safety, especially when violence or coercion is present. The clinical objective is sustained engagement and the parent's capacity to pursue health and functioning goals, rather than a narrow interpretation of success based on an isolated biological test.

Prevention and Preconception Planning

Preconception consultations can identify potentially harmful exposures, treat existing substance use disorders, review prescribed medications, discuss reproductive intentions, and support informed contraception choices where desired. Patients already receiving effective addiction treatment benefit from coordinated planning before conception, but a new pregnancy should prompt timely engagement even if planning was not possible. Care also includes vaccination, treatment of infectious diseases, nutritional support, and mental health assessment when indicated. CDC: clinical guidance on opioids and reproductive planning

Prevention begins with consistent and nonjudgmental access to health services. Routine counseling should communicate the fetal risks of alcohol, combustible tobacco, and cannabis exposure while explaining that prescribed treatments can have important protective benefits. Discussions should be repeated as needed, especially when pregnancy recognition, changing symptoms, or social conditions alter a patient's circumstances. ACOG: alcohol and fetal health ACOG, 2025: cannabis

Interpreting the Evidence: Established, Preliminary, and Limited Findings

Established recommendations rest on convergent clinical data and professional guidance, including methadone and buprenorphine for opioid use disorder in pregnancy; medically supervised care for potentially severe alcohol or benzodiazepine withdrawal; behavioral counseling for prenatal smoking cessation; and continuity across delivery and postpartum care. These recommendations are supported by varied study designs, and their ethical application still requires individualization. CDC, 2026 USPSTF, 2021

Strong general-population evidence does not always imply equally strong pregnancy-specific evidence. Contingency management is well supported for stimulant use disorder overall, while the prenatal evidence base is smaller and particular implementation questions remain. Nicotine replacement or other cessation pharmacotherapy requires a more individualized discussion in pregnancy than in nonpregnant adults. Medication for cannabis use disorder lacks an established prenatal pharmacologic standard. Digital support and text-based interventions can sometimes supplement care, but evidence for a given product, setting, and clinically important outcome must be evaluated independently. ASAM and AAAP, 2024 USPSTF, 2021

Association, causation, and confounding

Most exposures during pregnancy cannot be studied through randomized trials that intentionally assign hazardous substance use. Consequently, much evidence about fetal risk comes from prospective cohorts, retrospective records, or biological and animal studies. Such studies may be informative, but selection, residual confounding, incomplete exposure measurement, differences in co-use, and variations in prenatal care influence estimates. Even comparisons between two recommended medications may reflect who received each therapy and the services available to them. A scientifically responsible conclusion specifies the type of evidence and avoids claiming a uniquely causal effect when the data only establish association. Suarez et al., 2022 ACOG, 2025

Outcomes that matter to patients and infants

Evidence should be judged by more than test negativity or time in a program. Relevant outcomes include maternal survival, prevention of overdose, treatment retention, reduced harmful exposure, prenatal attendance, obstetric complications, patient functioning, child health, family safety, and access to support after discharge. Studies of neonatal withdrawal must also distinguish a predictable and manageable adaptation syndrome from broader long-term developmental outcomes. Follow-up beyond delivery is necessary to understand maternal and infant benefit. SAMHSA: postpartum care transitions

Frequently Asked Clinical Questions

Does any substance use during pregnancy mean the person has an addiction?

No. Substance exposure, risky use, physical dependence, and a diagnosed substance use disorder are clinically distinct. Some exposures warrant cessation counseling because of fetal risk even if the individual has no addiction. A disorder diagnosis requires assessment of symptoms, impairment, course, and substance-specific criteria. A toxicology result by itself does not diagnose addiction. USPSTF: drug screening

Should methadone or buprenorphine be stopped after a positive pregnancy test?

These medications are recommended for opioid use disorder during pregnancy, and effective treatment is generally continued under medical supervision. Sudden discontinuation or unsupervised tapering can destabilize care. Any proposed change should consider clinical stability, exposure risks, patient preference, and expert consultation. CDC, 2026

Is detoxification the same as addiction treatment?

No. Withdrawal management addresses acute physiological adaptation. Treatment for a substance use disorder also addresses recurrence risk, medication when indicated, behavioral mechanisms, co-occurring conditions, and social determinants. For opioid use disorder in pregnancy, medication treatment is preferred over withdrawal management alone. Severe alcohol and benzodiazepine withdrawal may require urgent supervised care. WHO pregnancy guidelines

What if the patient is using alcohol or benzodiazepines every day?

A clinician should assess physiological dependence, withdrawal history, co-prescribed drugs, medical stability, and obstetric risk before any cessation plan is made. Severe withdrawal from alcohol or benzodiazepines can provoke seizures or delirium. Patients with concerning symptoms or histories require urgent medical assessment. No home dosing or abrupt cessation instruction is appropriate without individualized care. ASAM, 2025

Can an infant experience withdrawal even when the parent is treated appropriately?

Yes. Neonatal opioid withdrawal can occur after exposure to methadone or buprenorphine and does not mean the patient received inappropriate treatment. Newborn teams monitor symptoms and provide supportive or medication-based care as needed. Evidence-based treatment for the pregnant patient remains fundamental to safety. CDC: OUD pregnancy treatment

Can a parent breastfeed while receiving treatment for opioid use disorder?

Many patients stable on methadone or buprenorphine can breastfeed with coordinated clinical guidance. The assessment changes with active nonprescribed substance use, some sedative exposures, or other infant and maternal conditions. Breastfeeding decisions should involve the parent and care team, with substance-specific evidence and continued follow-up. Academy of Breastfeeding Medicine, 2023

When is immediate medical attention necessary?

Emergency evaluation is indicated for suspected overdose, severe breathing impairment, seizures, delirium, severe agitation with dangerous physiological symptoms, chest pain, or signs of serious pregnancy complications. Naloxone and emergency medical services are appropriate for suspected opioid overdose. The safety of the pregnant patient is inseparable from fetal safety. CDC: opioid guidance

Clinical Synthesis

Substance use disorders during pregnancy are best managed through precise diagnosis, substance-specific treatment, reliable prenatal contact, and planned postpartum continuity. Effective addiction medications should be preserved where their benefits are established. Dangerous withdrawal syndromes demand medical supervision. Screening is an entry point to care; test results require interpretation. Counseling about alcohol, nicotine, cannabis, stimulants, and sedatives should reflect distinct patterns of risk and evidence. Neonatal observation, breastfeeding planning, and parenting support belong within coordinated maternal and infant care. The goal is sustained health, safety, and functioning for the pregnant patient and child through treatment systems that remain accessible after birth.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — the scientific chapter connecting diagnostic foundations, mechanisms, treatment, and recovery.

Opioid Use Disorder: Symptoms, Risks, and Treatment — criteria, medication treatment, and long-term care for opioid use disorder.

Alcohol Use Disorder: Signs, Diagnosis, and Treatment — clinical diagnosis and treatment across the course of alcohol-related disorder.

Alcohol Withdrawal: Symptoms, Risks, and Medical Care — medically dangerous withdrawal syndromes and professional management.

Cannabis Use Disorder: Symptoms, Diagnosis, and Recovery — cannabis-specific diagnostic and recovery science.

How to Quit Smoking: Effective Medications and Behavioral Support — evidence-based approaches to combustible tobacco cessation.

Perinatal Mental Health: Conditions, Symptoms, Screening, and Care — independent clinical assessment and treatment of perinatal mental health conditions.

Substance Use Disorders and Suicide Risk: Evidence, Assessment, and Safety — suicide risk evaluation and integrated safety planning.

References

American College of Obstetricians and Gynecologists. (2017). Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. Official guidance

American College of Obstetricians and Gynecologists. (2020). Tobacco and nicotine cessation during pregnancy. Committee Opinion No. 807. Official guidance

American College of Obstetricians and Gynecologists. (2025). Cannabis use during pregnancy and lactation. Clinical Consensus No. 10. Obstetrics and Gynecology, 146(4), 600–611. DOI: 10.1097/AOG.0000000000006053

American College of Obstetricians and Gynecologists. (n.d.). Fetal alcohol spectrum disorders: Frequently asked questions. Official source

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). Clinical practice guideline on the management of stimulant use disorder. Peer-reviewed guideline

American Society of Addiction Medicine and partner organizations. (2025). Joint clinical practice guideline on benzodiazepine tapering. Official guideline

Centers for Disease Control and Prevention. (2025). Opioid use and pregnancy: Clinical care. Official guidance

Centers for Disease Control and Prevention. (2025). Substance use during pregnancy. Official resource

Centers for Disease Control and Prevention. (2026). Polysubstance use during pregnancy. Official resource

Centers for Disease Control and Prevention. (2026). Treatment of opioid use disorder before, during, and after pregnancy. Official guidance

Harris, M., Schiff, D. M., Saia, K., Muftu, S., Standish, K. R., and Wachman, E. M. (2023). Academy of Breastfeeding Medicine Clinical Protocol #21: Breastfeeding in the setting of substance use and substance use disorder (revised 2023). Breastfeeding Medicine, 18(10), 715–733. DOI: 10.1089/bfm.2023.29256.abm

Jones, H. E., Kaltenbach, K., Heil, S. H., et al. (2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine, 363, 2320–2331. DOI: 10.1056/NEJMoa1005359

Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. Official guide

Substance Abuse and Mental Health Services Administration. (2026). Healthy Starts: Postpartum OUD care transitions for mother and infant. Official case study

Suarez, E. A., Huybrechts, K. F., Straub, L., et al. (2022). Buprenorphine versus methadone for opioid use disorder in pregnancy. New England Journal of Medicine, 387, 2033–2044. DOI: 10.1056/NEJMoa2203318

U.S. Preventive Services Task Force. (2020). Unhealthy drug use: Screening. Official recommendation

U.S. Preventive Services Task Force. (2021). Tobacco smoking cessation in adults, including pregnant persons: Interventions. Official recommendation

World Health Organization. (2014). Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Official guideline

Young, L. W., Ounpraseuth, S. T., Merhar, S. L., et al. (2023). Eat, Sleep, Console approach or usual care for neonatal opioid withdrawal. New England Journal of Medicine, 388, 2326–2337. DOI: 10.1056/NEJMoa2214470